XRAYDENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. (XRAY) sells dental and orthodontic equipment, software, and consumables. The next catalyst is Sep 30, 2026 — Trump Administration Trade Policy, which will test the company’s exposure to U.S. import tariffs on medical devices. The event will scrutinize how trade policy shifts affect supply chains and pricing power.
- Revenue fell 3.0% YoY to $3.62B, with a net loss of $445M and a -12.3% net margin.
- Free cash flow of $219M suggests operational discipline, but leverage at 1.70x Debt/Equity remains a concern.
- Shareholders’ equity of $1.34B and a diluted EPS of $0.18 highlight a cash-burn concern amid declining revenue.
The Read
4% on a Q4 EPS miss offset by a $120 million restructuring plan, but then fell about 11.
The schedule
- Wed30Sep
This event will test the company's exposure to trade policy shifts, particularly in the context of Trump's potential return to power. The prior event in September 2026 showed a bearish outcome, but the current environment may differ due to the evolving trade landscape.
- Fri2Oct
This news event could provide clarity on the company's strategic direction, particularly regarding its recent restructuring efforts and product launches. The market will be watching for any signs of improved operational efficiency or new revenue streams.
- Thu15Oct
This event will test the company's ability to capitalize on industry trends and customer demand at a major dental trade show. The prior event in 2026 showed a bearish outcome, but the current environment may differ due to the evolving trade landscape.
- Thu5Nov
This earnings report will test the company's ability to maintain margins amid macroeconomic headwinds and trade policy uncertainty. The Q2 2026 print showed a bearish outcome, but the recent rebound suggests a potential for a more neutral or slightly bullish outcome.
- Tue9Feb
- Fri26Feb
Dentsply Sirona to Host Fourth Quarter and Full Year ...
- Tue11May
- Thu5Aug
Past
- Thu6Aug
Actual outcome: Bear · $11.61 at outcome
DENTSPLY SIRONA reported Q2 earnings of $0.18 per share, matching the estimate of $0.36 per share, but the stock fell 11.8% due to weaker-than-expected revenue of $898 million, down 4.1% on a reported basis. The guidance and restructuring plan did not sufficiently offset concerns about declining volumes and distributor inventory reductions in Europe, leading to a bearish price reaction.
Market will scrutinize the Q2 print at $11.65 to see if the $120M restructuring plan announced in Q1 is buffering bottom-line erosion, aiming for a favorable $12.35 or slipping to an adverse $10.65.
- Thu5Mar
Actual outcome: Bear · $11.75 at outcome
Dentsply Sirona shares declined 11.9% after the company reported a Q4 earnings miss and issued a softer 2026 revenue outlook of $3.5 billion to $3.6 billion. While the company announced a $120 million restructuring plan and secured FDA clearance for a new dental-dedicated MRI system, ongoing macroeconomic headwinds and weak dentist capital expenditure sentiment ultimately weighed heavily on the stock.
- Thu26Feb
Actual outcome: Bull · $13.44 at outcome
Dentsply Sirona reported a slight miss on Q4 adjusted EPS ($0.27 vs. $0.28 estimate) and issued a softer-than-expected 2026 sales outlook of $3.5 billion to $3.6 billion. However, the stock rallied because the company simultaneously unveiled a $120 million restructuring plan, which investors cheered as a proactive step to improve operational efficiency and margins.